Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 28, 2007
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval for its LIVIAN™ cardiac resynchronization therapy defibrillator...
-
Dec 21, 2007TAXUS Liberte has more CE Mark-approved indications than any other drug-eluting stent
Boston Scientific Corporation (NYSE: BSX) announced today that its TAXUS® Liberte™ paclitaxel-eluting coronary stent system has received...
-
Dec 13, 2007
Boston Scientific Corporation (NYSE: BSX) and Avista Capital Partners, a leading private equity firm, today jointly announced the...
-
Nov 29, 2007
Boston Scientific Corporation (NYSE: BSX) today welcomed the recommendation of a U.S. Food and Drug Administration (FDA) advisory panel to approve...
-
Nov 28, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the BMO Capital Markets Healthcare Conference, which is being held...
-
Nov 21, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held November 27...
-
Nov 19, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that an amended agreement has been reached to settle claims associated with a series of...
-
Nov 6, 2007
Boston Scientific Corporation (NYSE: BSX) and GE Healthcare (NYSE: GE) today announced the industry's first patient data...
-
Nov 5, 2007
Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive agreement for the sale of its Cardiac Surgery and Vascular...
-
Oct 31, 2007
Boston Scientific Corporation (NYSE: BSX) announced today that a jury in U.S. District Court in San Francisco has found that Boston Scientific...
-
Oct 26, 2007Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company
Boston Scientific today announced that Keith Dawkins, M.D., and Takahiro Uchida, M.D., will be joining the Company's Clinical Sciences...
-
Oct 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced positive three-year results from its CABERNET and BEACH carotid artery...
-
Oct 22, 2007TAXUS IV study demonstrates long-term safety and efficacy of TAXUS drug- eluting stent compared to bare-metal stent
Boston Scientific Corporation (NYSE: BSX) today announced five-year and final follow- up data from its TAXUS IV clinical trial. The...
-
Oct 22, 2007TAXUS ATLAS studies also reinforce deliverability of TAXUS® Liberte® drug-eluting stent in long lesions and small vessels
Boston Scientific Corporation (NYSE: BSX) today announced nine-month data from the pivotal TAXUS ATLAS Small Vessel and Long Lesion...
-
Oct 22, 2007
Boston Scientific Corporation (NYSE: BSX) today welcomed results from the SPIRIT III Clinical Trial, which continue to support the...
-
Oct 21, 2007
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,000 patients from its TAXUS ARRIVE 1...
-
Oct 19, 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2007, as well as guidance for...
-
Oct 17, 2007Approximately 2,300 positions to be eliminated worldwide
Boston Scientific Corporation (NYSE: BSX) today announced several new initiatives designed to enhance short- and long-term shareholder value,...
-
Oct 16, 2007
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular...
-
Oct 9, 2007
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval of its CONFIENT™ implantable cardioverter defibrillator (ICD). This...
-
Oct 1, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Sep 14, 2007
Boston Scientific Corporation (NYSE: BSX) today released data reflecting experience from the first 15,000 patients(1) monitored wirelessly on the...
-
Sep 6, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that the Company's Board of Directors has elected Ray Elliott as a Director. Mr. Elliott,...
-
Sep 5, 2007
Boston Scientific Corporation (NYSE: BSX) today announced results from the TAXUS WOMAN study, a gender specific analysis of the...
-
Sep 4, 2007TAXUS® Stent shows no additional very late stent thrombosis
Boston Scientific Corporation (NYSE: BSX) today announced five-year and final results from its TAXUS II clinical trial,...
-
Sep 2, 2007OLYMPIA Launch Phase Results Show Positive Outcomes in Diabetic Patients
Boston Scientific Corporation (NYSE: BSX) today announced one-year results from the European and Intercontinental launch phases...
-
Aug 30, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that three of its subsidiaries, Guidant Corporation, Cardiac Pacemakers Inc. and Guidant...
-
Aug 29, 2007
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the European...
-
Aug 28, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bear Stearns 20th Annual Healthcare Conference, which is being held...
-
Aug 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that it has successfully amended its $2 billion revolving line of credit and $5 billion...
-
Aug 16, 2007Transaction Would Advance Company's Plan to Divest Non-Strategic Assets and Strengthen Operating and Financial Performance
Boston Scientific Corporation (NYSE: BSX) today announced its intention to explore the sale of its Cardiac Surgery and Vascular Surgery businesses...
-
Aug 9, 2007BSC to assume sole control of Pain Management business and emerging indications program, Advanced Bionics principals to purchase Auditory business and drug pump program
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an agreement to amend its merger agreement with Advanced Bionics,...
-
Aug 2, 2007Endosurgery group to remain wholly owned by Boston Scientific
Boston Scientific Corporation (NYSE: BSX) today provided an update on its plans to strengthen operating and financial performance as part of its...
-
Jul 24, 2007
Boston Scientific Corporation (NYSE: BSX) today announced its intention to explore the sale of its fluid management business as part of the...
-
Jul 20, 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the second quarter ended June 30, 2007, as well as guidance for net...
-
Jul 19, 2007TAXUS PERSEUS clinical program to evaluate platinum enhanced drug-eluting stent
Boston Scientific Corporation (NYSE: BSX) today announced the beginning of clinical trial enrollment in studies evaluating its third-generation...
-
Jul 17, 2007
Boston Scientific Corporation (NYSE: BSX) today announced the successful implantation of the Company's TAXUS® Petal™ Bifurcation...
-
Jul 13, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that an agreement has been reached to settle claims associated with a series of product...
-
Jul 10, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2007...
-
Jul 2, 2007Hardware and software innovations offer new benefits to physicians and patients
Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Precision Plus™ Spinal Cord Stimulation (SCS) System, the world's...
-
Jun 25, 2007
Boston Scientific Corporation (NYSE: BSX) today announced it has signed a definitive agreement to acquire Remon Medical Technologies Inc., a...
-
Jun 21, 2007Deal Follows Successful Four-Year Exclusive Distribution of Prolieve® Thermodilatation System
Boston Scientific Corporation (NYSE: BSX) today announced that it has purchased technology for treating symptomatic benign prostatic hyperplasia...
-
Jun 8, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in Goldman Sachs' 28th Annual Healthcare Conference, which is being held June...
-
Jun 4, 2007
Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an article in the Journal of American College of Cardiology (JACC)...
-
May 31, 2007Study seeks to confirm the safety and efficacy of systems in routine clinical practice
Boston Scientific Corporation (NYSE: BSX) today announced enrollment of the first patient in the SONOMA post-market approval study of the Company's...
-
May 24, 2007Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease
Boston Scientific Corporation (NYSE: BSX) today announced that it has received CE Mark for its TAXUS® Liberte™ Long...
-
May 22, 2007SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of additional data from the SPIRIT FIRST, II and III...
-
May 22, 2007Study highlights importance of antiplatelet therapy compliance
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of more than 7,000 patients from its ARRIVE...
-
May 22, 2007Trial results report no new stent thrombosis after two years in high-risk patient population
Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS VI clinical trial. The data...
-
May 18, 2007Group supports call for limiting greenhouse gas emissions
Boston Scientific Corporation (NYSE: BSX) today announced that it has joined the U.S. Climate Action Partnership (USCAP). USCAP was formed as a...
-
May 18, 2007Company anticipates broad range of clinical results on endoscopic technologies
Boston Scientific Corporation (NYSE: BSX) today announced that results from several clinical studies designed to determine the safety and efficacy...
-
May 17, 2007Single-operator system allows unprecedented visual access to bile duct
Boston Scientific Corporation (NYSE: BSX) today announced worldwide commercial availability of its SpyGlass™ Direct Visualization System for...
-
May 15, 2007Company to release broad range of clinical data on leading drug-eluting stent portfolio
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the annual Paris...
-
May 14, 2007More than 23,000 patients now enrolled in TAXUS OLYMPIA registry
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the European and Intercontinental phases (II and III)...
-
May 10, 2007New data provide support for minimally invasive treatment of atrial fibrillation (AF)(1)
Boston Scientific Corporation (NYSE: BSX) today commented on data released on May 9th at the American Association for Thoracic Surgery (AATS)...
-
May 9, 2007
Boston Scientific Corporation (NYSE: BSX) today released data reflecting clinical event notification statistics from the first 10,000 patients(1)...
-
May 8, 2007Reimbursement granted by National Health Insurance System
Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS® Express2™ paclitaxel-eluting coronary stent system in Japan....
-
May 3, 2007RENAISSANCE trial demonstrates durable results for Company's Express® SD Renal Stent in treating hypertensive patients with severe renal artery stenosis
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from its RENAISSANCE study, which was designed to evaluate...
-
May 1, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice...
-
Apr 26, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in its SYNTAX clinical trial. SYNTAX is the first trial...
-
Apr 24, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being...
-
Apr 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2007, as well as guidance for...
-
Apr 17, 2007Product provides enhanced control for accessing desired vessel location
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of the ACUITY® Steerable left...
-
Apr 16, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2007...
-
Apr 16, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that the Company has resolved the deficiencies in the warning letter issued by the U.S....
-
Apr 3, 2007
Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Apr 2, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its MAPS™ clinical trial. The MAPS trial (Matrix And...
-
Mar 26, 2007BTK CHILL study demonstrates high rate of limb protection at one year
Boston Scientific Corporation (NYSE: BSX) today announced excellent one-year results from its Below-The-Knee (BTK) CHILL study,...
-
Mar 25, 2007
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from the TAXUS V In-Stent Restenosis (ISR) trial,...
-
Mar 25, 2007Two-year review of TAXUS Stent safety data presented at ACC
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from its ARRIVE 1 registry and the combined one-year...
-
Mar 24, 2007Results reaffirm strength of Boston Scientific's dual drug-eluting stent program
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of the pivotal SPIRIT III clinical trial, which reaffirmed...
-
Mar 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced a program designed to improve patient compliance with physician-prescribed anti-platelet...
-
Mar 22, 2007Smallest Dual Chamber System offered in Japan provides enhanced therapies to patients at risk of sudden cardiac death
Boston Scientific Corporation (NYSE: BSX) today announced regulatory approval and market launch in Japan for its VITALITY™ DR implantable...
-
Mar 20, 2007Company to host analyst meeting and symposium on drug-eluting stents
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the annual...
-
Mar 13, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Lehman Brothers Health Care Conference, which is being held March 19...
-
Mar 12, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that its Board of Directors has authorized management to explore an initial public...
-
Mar 8, 2007
Boston Scientific Corporation (NYSE: BSX) today announced several enhancements related to the governance of the company. "Boston Scientific is...
-
Mar 6, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen Health Care Conference, which is being held March 12 - 15 in...
-
Mar 5, 2007
Boston Scientific Corporation (NYSE: BSX) released the following statement today in response to a request for information relating to its TAXUS®...
-
Feb 28, 2007Campaign spokesperson - a Formula race car driver, amputee, and chronic pain patient - to promote public awareness
Boston Scientific Corporation (NYSE: BSX) announced today the launch of its Neuromodulation Group's Race Against Pain public outreach campaign to...
-
Feb 12, 2007
Boston Scientific Corporation (NYSE: BSX) today commented on results from a Swedish registry assessing the long-term outcomes of drug-eluting...
-
Feb 12, 2007
Boston Scientific Corporation (NYSE: BSX) today welcomed the online release of several important articles scheduled for publication in the March...
-
Feb 5, 2007DES patients have significantly lower rates of death, heart attack and re-intervention than BMS patients
Boston Scientific Corporation (NYSE: BSX) today welcomed data from a study showing that drug- eluting stents (DES) have substantially lower rates of...
-
Feb 2, 2007
Boston Scientific Corporation (NYSE: BSX) today commented on a proposed National Coverage Determination (NCD) released by the Centers for Medicare...
-
Feb 1, 2007Company provides guidance for first quarter 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2006, as well as...
-
Jan 31, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended...
-
Jan 29, 2007Longer balloon gives physicians broader treatment options in peripheral artery disease
Boston Scientific Corporation (NYSE: BSX) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to expand its...
-
Jan 25, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended...
-
Jan 18, 2007New U.S. shelf life is longer than any competing drug-eluting stent product
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of...
-
Jan 17, 2007Court Orders Injunction and Damages
Boston Scientific Corporation (NYSE: BSX) announced today that it and Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI; TSX: ANP) won a patent...
-
Jan 16, 2007
Boston Scientific Corporation (NYSE: BSX) commented on a decision today by the U.K. Court of Appeal that affirmed an earlier ruling by a lower...
-
Jan 12, 2007Lower rates of re-intervention and major adverse events reported for the TAXUS Stent in study of diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of an independent study demonstrating that Boston Scientific's TAXUS®...
-
Jan 11, 2007Boston Scientific only company to offer two distinct drug-eluting stent platforms
Boston Scientific Corporation (NYSE:BSX) today announced the international launch and first implantation of the PROMUS(TM) Everolimus-Eluting...
-
Jan 10, 2007
Boston Scientific Corporation (NYSE: BSX) today announced preliminary, unaudited net sales for its fourth quarter and full year ended December 31,...
-
Jan 8, 2007Plan to increase innovation, productivity and competitiveness
Boston Scientific Corporation (NYSE: BSX) today announced a plan to reallocate its cardiac rhythm management (CRM) research and development...
-
Jan 4, 2007Acquisition demonstrates Company's commitment to leadership in treating carotid artery disease
Boston Scientific Corporation (NYSE: BSX) today announced it has acquired EndoTex Interventional Systems, Inc. The acquisition follows the Food and...
-
Jan 3, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the JP Morgan Health Care Conference, which is being held January 8 - 11 in...
-
Jan 2, 2007Trial highlights the importance of appropriate pacing for patients at risk of sudden cardiac death
Boston Scientific Corporation (NYSE: BSX) today announced that results of the largest implantable cardioverter defibrillator (ICD) study to date,...